PET Biomarkers in Treatment Resistant Depression
Stopped early · Phase 4
Conditions studied: Major Depressive Disorder
In brief
The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor (MAOI) medication in this population.
Key facts
- Study ID
- NCT01031810
- Run by
- New York State Psychiatric Institute
- People needed
- 13
- Starts
- 2009-11-01
- Expected to finish
- 2013-03-01
- Last updated by the study team
- 2014-09-18
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- New York State Psychiatric Institute — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.